Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXP001 ibuprofen for gastroduodenal irritation
NCT02521207Phase 1Completed
- Sponsor
- Oxford Pharmascience
- Start
- Jul 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oxprofen in gastroduodenal erosions (4 arms), sponsored by Oxford Pharmascience. Primary endpoints: Peak Plasma Concentration at Day 4, Area Under the Curve at Day 4 and 2 more. Started Jul 2015; status: completed.
02
Drugs
oxprofen
03
Conditions
gastroduodenal erosions
Beyond the preview
Go deeper on NCT02521207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521207.